XXXX , outcomes by stage: The MSK experience.

@entity43 @entity1 @entity397
OBJECTIVE: @entity43 ( @entity43 ) are rare, and uncertainty exists as to the optimal treatment paradigm and validity of the FIGO staging system, especially in early-stage disease. METHODS: We performed a retrospective cohort study of all OCCC @entity1 diagnosed and treated at Memorial Sloan Kettering Cancer Center between January 1996 and December 2013. Progression-free survival (PFS) and overall survival (OS) were calculated by stage and race, and comparisons were made using the log-rank test. Statistical significance was set at p<0.05. Type and duration of treatment were also recorded. RESULTS: There were 177 evaluable @entity1 . The majority of @entity1 were stage I at diagnosis (110/177, 62.2%). Of these, 60/110 (54.6%) were stage IA, 31/110 (28.2%) were stage IC on the basis of @entity397 -only, and 19/110 (17.3%) were stage IC on the basis of surface involvement and/or positive cytology of ascites or washings. @entity1 with stage IA and IC based on @entity397 -only had similar PFS/OS outcomes. @entity1 with stage IC based on surface involvement and/or positive cytology had a statistically significant decrement in PFS/OS. Stage was an important indicator of PFS/OS, while race was not. CONCLUSIONS: OCCC often presents in early stage. @entity1 with stage IA OCCC have excellent prognosis, and future studies should explore whether they benefit from adjuvant chemotherapy. @entity1 with IC OCCC need further staging clarification, as surgical @entity397 alone affords better prognosis than surface involvement and/or positive cytology. @entity1 with advanced OCCC have poor survival and are often chemotherapy resistant/refractory. New treatment paradigms are needed.
